Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

Michelle H. Larsen, Karolin Biermann, Bing Chen, Tsungda Hsu, Vasan K. Sambandamurthy, Andrew A. Lackner, Pyone Pyone Aye, Peter Didier, Dan Huang, Linyun Shao, Huiyong Wei, Norman L. Letvin, Richard Frothingham, Barton F. Haynes, Zheng W. Chen, William R. Jacobs

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Tuberculosis (TB) remains a global health burden for which safe vaccines are needed. BCG has limitations as a TB vaccine so we have focused on live attenuated Mycobacterium tuberculosis mutants as vaccine candidates. Prior to human studies, however, it is necessary to demonstrate safety in non-human primates (NHP). In this study, we evaluate the safety and efficacy of two live attenuated M. tuberculosis double deletion vaccine strains mc26020 (ΔlysA ΔpanCD) and mc26030 (ΔRD1 ΔpanCD) in cynomolgus macaques. In murine models, mc26020 is rapidly cleared while mc26030 persists. Both mc26020 and mc26030 were safe and well tolerated in cynomolgus macaques. Following a high-dose intrabronchial challenge with virulent M. tuberculosis, mc26020-vaccinates were afforded a level of protection intermediate between that elicited by BCG vaccination and no vaccination. BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc26030 vaccinates, but survival did not differ among the groups.

Original languageEnglish (US)
Pages (from-to)4709-4717
Number of pages9
JournalVaccine
Volume27
Issue number34
DOIs
StatePublished - Jul 23 2009

Fingerprint

Tuberculosis Vaccines
Mycobacterium tuberculosis
Mycobacterium bovis
Primates
Vaccines
tuberculosis
Macaca
vaccines
Safety
Macaca fascicularis
Vaccination
Tuberculosis
Clinical Pathology
vaccination
Survival
animal models
mutants
dosage

Keywords

  • BCG
  • Mycobacteria
  • Mycobacterium
  • Non-human primate
  • Safety
  • Tuberculosis
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. / Larsen, Michelle H.; Biermann, Karolin; Chen, Bing; Hsu, Tsungda; Sambandamurthy, Vasan K.; Lackner, Andrew A.; Aye, Pyone Pyone; Didier, Peter; Huang, Dan; Shao, Linyun; Wei, Huiyong; Letvin, Norman L.; Frothingham, Richard; Haynes, Barton F.; Chen, Zheng W.; Jacobs, William R.

In: Vaccine, Vol. 27, No. 34, 23.07.2009, p. 4709-4717.

Research output: Contribution to journalArticle

Larsen, MH, Biermann, K, Chen, B, Hsu, T, Sambandamurthy, VK, Lackner, AA, Aye, PP, Didier, P, Huang, D, Shao, L, Wei, H, Letvin, NL, Frothingham, R, Haynes, BF, Chen, ZW & Jacobs, WR 2009, 'Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates', Vaccine, vol. 27, no. 34, pp. 4709-4717. https://doi.org/10.1016/j.vaccine.2009.05.050
Larsen, Michelle H. ; Biermann, Karolin ; Chen, Bing ; Hsu, Tsungda ; Sambandamurthy, Vasan K. ; Lackner, Andrew A. ; Aye, Pyone Pyone ; Didier, Peter ; Huang, Dan ; Shao, Linyun ; Wei, Huiyong ; Letvin, Norman L. ; Frothingham, Richard ; Haynes, Barton F. ; Chen, Zheng W. ; Jacobs, William R. / Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. In: Vaccine. 2009 ; Vol. 27, No. 34. pp. 4709-4717.
@article{9782cede944f4f8cb8e076874de4f3bb,
title = "Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates",
abstract = "Tuberculosis (TB) remains a global health burden for which safe vaccines are needed. BCG has limitations as a TB vaccine so we have focused on live attenuated Mycobacterium tuberculosis mutants as vaccine candidates. Prior to human studies, however, it is necessary to demonstrate safety in non-human primates (NHP). In this study, we evaluate the safety and efficacy of two live attenuated M. tuberculosis double deletion vaccine strains mc26020 (ΔlysA ΔpanCD) and mc26030 (ΔRD1 ΔpanCD) in cynomolgus macaques. In murine models, mc26020 is rapidly cleared while mc26030 persists. Both mc26020 and mc26030 were safe and well tolerated in cynomolgus macaques. Following a high-dose intrabronchial challenge with virulent M. tuberculosis, mc26020-vaccinates were afforded a level of protection intermediate between that elicited by BCG vaccination and no vaccination. BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc26030 vaccinates, but survival did not differ among the groups.",
keywords = "BCG, Mycobacteria, Mycobacterium, Non-human primate, Safety, Tuberculosis, Vaccine",
author = "Larsen, {Michelle H.} and Karolin Biermann and Bing Chen and Tsungda Hsu and Sambandamurthy, {Vasan K.} and Lackner, {Andrew A.} and Aye, {Pyone Pyone} and Peter Didier and Dan Huang and Linyun Shao and Huiyong Wei and Letvin, {Norman L.} and Richard Frothingham and Haynes, {Barton F.} and Chen, {Zheng W.} and Jacobs, {William R.}",
year = "2009",
month = "7",
day = "23",
doi = "10.1016/j.vaccine.2009.05.050",
language = "English (US)",
volume = "27",
pages = "4709--4717",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "34",

}

TY - JOUR

T1 - Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

AU - Larsen, Michelle H.

AU - Biermann, Karolin

AU - Chen, Bing

AU - Hsu, Tsungda

AU - Sambandamurthy, Vasan K.

AU - Lackner, Andrew A.

AU - Aye, Pyone Pyone

AU - Didier, Peter

AU - Huang, Dan

AU - Shao, Linyun

AU - Wei, Huiyong

AU - Letvin, Norman L.

AU - Frothingham, Richard

AU - Haynes, Barton F.

AU - Chen, Zheng W.

AU - Jacobs, William R.

PY - 2009/7/23

Y1 - 2009/7/23

N2 - Tuberculosis (TB) remains a global health burden for which safe vaccines are needed. BCG has limitations as a TB vaccine so we have focused on live attenuated Mycobacterium tuberculosis mutants as vaccine candidates. Prior to human studies, however, it is necessary to demonstrate safety in non-human primates (NHP). In this study, we evaluate the safety and efficacy of two live attenuated M. tuberculosis double deletion vaccine strains mc26020 (ΔlysA ΔpanCD) and mc26030 (ΔRD1 ΔpanCD) in cynomolgus macaques. In murine models, mc26020 is rapidly cleared while mc26030 persists. Both mc26020 and mc26030 were safe and well tolerated in cynomolgus macaques. Following a high-dose intrabronchial challenge with virulent M. tuberculosis, mc26020-vaccinates were afforded a level of protection intermediate between that elicited by BCG vaccination and no vaccination. BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc26030 vaccinates, but survival did not differ among the groups.

AB - Tuberculosis (TB) remains a global health burden for which safe vaccines are needed. BCG has limitations as a TB vaccine so we have focused on live attenuated Mycobacterium tuberculosis mutants as vaccine candidates. Prior to human studies, however, it is necessary to demonstrate safety in non-human primates (NHP). In this study, we evaluate the safety and efficacy of two live attenuated M. tuberculosis double deletion vaccine strains mc26020 (ΔlysA ΔpanCD) and mc26030 (ΔRD1 ΔpanCD) in cynomolgus macaques. In murine models, mc26020 is rapidly cleared while mc26030 persists. Both mc26020 and mc26030 were safe and well tolerated in cynomolgus macaques. Following a high-dose intrabronchial challenge with virulent M. tuberculosis, mc26020-vaccinates were afforded a level of protection intermediate between that elicited by BCG vaccination and no vaccination. BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc26030 vaccinates, but survival did not differ among the groups.

KW - BCG

KW - Mycobacteria

KW - Mycobacterium

KW - Non-human primate

KW - Safety

KW - Tuberculosis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=67649482280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649482280&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.05.050

DO - 10.1016/j.vaccine.2009.05.050

M3 - Article

C2 - 19500524

AN - SCOPUS:67649482280

VL - 27

SP - 4709

EP - 4717

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 34

ER -